UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 9, 2005

PSS WORLD MEDICAL, INC.

(Exact name of Registrant as specified in its charter)

Commission File Number: 0-23832

Florida	59-2280364
(State or other jurisdiction	(IRS Employer
of incorporation or organization)	Identification Number)

4345 Southpoint Blvd.
Jacksonville, Florida	32216
(Address of principal executive offices)	(Zip code)


Registrant’s telephone number, including area code	(904) 332-3000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01.

Other Events.

On September 12, 2005, PSS World Medical, Inc. (the “Company”) issued a press release in which the Company announced that the Company and all other defendants reached an agreement on September 9, 2005, with the plaintiff and the certified class of persons who held Company common stock on March 26, 1998 to settle all claims alleged in the class action lawsuit entitled Jack Hirsch v. PSS World Medical, Inc., et al., Civil Action No. 3:98-CV 502-J-32TEM. This press release is attached as Exhibit 99.1 to this report and is incorporated herein by reference. The settlement is subject to the execution of formal documentation and to final court approval.

The settlement agreement between the plaintiffs, the Company, and the other defendants requires the Company to make an aggregate payment of $16.5 million, of which $13.2 million will be recovered through exisiting insurance policies, into a settlement fund (the “Settlement Fund”) to be used, among other things, to pay the fees and expenses of plaintiffs’ counsel, the costs of administering the Settlement Fund, and the plaintiffs. As part of the settlement, the plaintiffs will release the Company and all other defendants from any and all claims that were asserted or that could have been asserted in the lawsuit. Neither the Company nor the other defendants admit any wrongdoing or liability as part of the settlement.

Item 9.01.		Financial Statements and Exhibits.
	(a)	Not Applicable.
	(b)	Not Applicable.
	(c)	Not Applicable.
	(d)	Exhibits:

	Exhibit Number	Description

	99.1	Press Release dated September 12, 2005.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: September 15, 2005

PSS WORLD MEDICAL, INC.

By: /s/ David M. Bronson

Name:

David M. Bronson

Title:

Executive Vice President and Chief Financial Officer

EXHIBIT INDEX

99.1

Press Release dated September 12, 2005.